Milestone Pharma Files 8-K on Shareholder Nominations
Ticker: MIST · Form: 8-K · Filed: Mar 19, 2025 · CIK: 1408443
Sentiment: neutral
Topics: shareholder-nomination, corporate-governance
TL;DR
Milestone Pharma filed an 8-K for shareholder nominations. Keep an eye on board changes.
AI Summary
Milestone Pharmaceuticals Inc. filed an 8-K on March 19, 2025, reporting a shareholder nomination event as of March 18, 2025. The filing details the company's incorporation in Quebec and its principal executive offices located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Quebec, H4M 2X6.
Why It Matters
This filing indicates potential changes or activism within Milestone Pharmaceuticals due to shareholder nominations, which could impact the company's strategic direction.
Risk Assessment
Risk Level: medium — Shareholder nominations can signal activism or disputes, potentially leading to changes in company strategy or leadership.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- March 18, 2025 (date) — Earliest event reported
- March 19, 2025 (date) — Date of report
- 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Quebec, H4M 2X6 (location) — Principal executive offices
FAQ
What specific event triggered this 8-K filing?
The 8-K filing was triggered by shareholder nominations pursuant to Exchange Act Rule 14a-11.
When was the earliest event reported in this filing?
The earliest event reported was on March 18, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Milestone Pharmaceuticals Inc.
Where are Milestone Pharmaceuticals Inc.'s principal executive offices located?
The principal executive offices are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Quebec, H4M 2X6.
What is the company's state of incorporation?
The company's state of incorporation is Quebec.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 19, 2025 regarding Milestone Pharmaceuticals Inc. (MIST).